Attached files
| file | filename |
|---|---|
| EX-99.1 - EXHIBIT 99.1 - Vaxart, Inc. | ex99-1.htm |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): February 12, 2013
Biota Pharmaceuticals, Inc.
(Exact name of registrant as specified in its charter)
|
Delaware
|
001-35285 |
59-1212264
|
|
(State or other jurisdiction
of incorporation)
|
(Commission
File Number)
|
(IRS Employer
Identification No.)
|
|
12270 Wilkins Avenue
Rockville, Maryland
|
20852
|
|
|
(Address of principal executive offices)
|
(Zip Code)
|
|
Registrant’s telephone number, including area code: (301) 770-3099
Not applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 2.02 Results of Operations and Financial Condition
On February 12, 2013, Biota Pharmaceuticals, Inc. issued a press release announcing financial results for the quarter ended December 31, 2012 and related information. A copy of the press release is attached as Exhibit 99.1.
The information in this Item 2.02 is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934 or otherwise subject to the liabilities of that Section. The information in this Item 2.02 shall not be incorporated by reference into any registration statement or other document filed with the Securities and Exchange Commission..
Item 9.01 Financial Statements and Exhibits
(d) Exhibits
|
99.1
|
Press release dated February 12, 2013.
|
|
|
*
|
Exhibit 99.1 is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934 or otherwise subject to the liabilities of that Section, nor shall it be incorporated by reference into any registration statement or other document filed with the Securities and Exchange Commission.
|
|
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
Biota Pharmaceuticals, Inc.
|
||
|
Date: February 12, 2013
|
/s/ Russell H Plumb
|
|
|
Name:
|
Russell H Plumb
|
|
|
Title:
|
Chief Executive Officer and President
|
|
|
(Duly Authorized Officer)
|
||
EXHIBIT INDEX
|
Exhibit
Number
|
Description
|
|
|
99.1
|
Press release dated February 12, 2013.
|